With the start of CFTR modulator therapy, the therapeutic options for people with CF have improved immensely and life expectancy increased to an average of up to 50 years (Bell et al., 2020), but 44% of European CF patients are still chronically colonized with P. aeruginosa (Orenti et al., 2021). The gene discussed is CFTR; the disease is cystic fibrosis.